Jeffrey B Locke

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 8

Top Topics

Combination Therapy

Candida Albicans

Genetic Diversity

Helicobacter Pylori

Top Venues

Antimicrobial agents and chemotherapy

The Journal of antimicrobial chemotherapy

Infectious diseases in obstetrics and gynecology

This page only lists publications with an associated author ORCID identifier.

Publications

Jeffrey B Locke, Chris M Pillar, Mariana Castanheira, Cecilia G Carvalhaes, David R Andes, Jalal A Aram, Christina Andrzejewski, Ken Bartizal, Anita F Das, Taylor Sandison, George R Thompson, Peter G Pappas
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis. Antimicrobial agents and chemotherapy (2024)
Jeffrey B Locke, Chris M Pillar, Mariana Castanheira, Cecilia G Carvalhaes, David R Andes, Jalal A Aram, Christina Andrzejewski, Ken Bartizal, Anita F Das, Taylor Sandison, George R Thompson, Peter G Pappas
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis. Antimicrobial agents and chemotherapy 68 (5) (2024)
Jeffrey B Locke, Chris M Pillar, Mariana Castanheira, Cecilia G Carvalhaes, David R Andes, Jalal A Aram, Christina Andrzejewski, Ken Bartizal, Anita F Das, Taylor Sandison, George R Thompson, Peter G Pappas
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis. Antimicrobial agents and chemotherapy 68 (5) (2024)
Jeffrey B Locke, Chris M Pillar, Mariana Castanheira, Cecilia G Carvalhaes, David R Andes, Jalal A Aram, Christina Andrzejewski, Ken Bartizal, Anita F Das, Taylor Sandison, George R Thompson, Peter G Pappas
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis. Antimicrobial agents and chemotherapy 68 (5) (2024)
Jeffrey B Locke, Chris M Pillar, Mariana Castanheira, Cecilia G Carvalhaes, David R Andes, Jalal A Aram, Christina Andrzejewski, Ken Bartizal, Anita F Das, Taylor Sandison, George R Thompson, Peter G Pappas
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis. Antimicrobial agents and chemotherapy 68 (5) (2024)
Douglas E Zuill, Amanda L Almaguer, Joanna Donatelli, Maiken Cavling Arendrup, Jeffrey B Locke
Development and preliminary validation of a modified EUCAST yeast broth microdilution MIC method with Tween 20-supplemented medium for rezafungin. The Journal of antimicrobial chemotherapy (2023)
Maiken Cavling Arendrup, Sevtap Arikan-Akdagli, Mariana Castanheira, Jesus Vicente Guinea, Jeffrey B Locke, Joseph Meletiadis, Óscar Zaragoza
Multicentre validation of a modified EUCAST MIC testing method and development of associated epidemiologic cut-off (ECOFF) values for rezafungin. The Journal of antimicrobial chemotherapy (2022)
Jeffrey B Locke, Amanda L Almaguer, Joanna L Donatelli, Ken F Bartizal
Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species. Infectious diseases in obstetrics and gynecology 2018 (2018)